Category Archives: ceritinib – Zykadia from Novartis

Great page with very high quality info on AlK & AlK inhibitors

Below is a link to a page that provides comprehensive regularly updated info written by two ALK research oncologists Dr. Alice Shaw and Ben Solomon, Phd (then edited by three people). It is written for an audience of doctors and … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments | Leave a comment

Zykadia (ceritinib) by Novartis is approved for first line use in US

As of May 26, 2017 the FDA approved ceritinib for first line use. So it will go head to head with crizotinib. One article said a similar EU approval was likely “in coming weeks”. The results are based on the … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research | Leave a comment

Update on Novartis and Ariad trials

As of Dec. 6, 2016 Novartis and Ariad announced research updates In Phase III study by Novartis on Zykadia® (ceritinib) as a first-line treatment, they found a 45% reduction in the risk of disease progression. The study found a median progression free survival … Continue reading

Posted in Anaplastic Large-Cell Lymphomas, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research | Leave a comment

Outcomes for ALK+ patients

Abstract e20550 is from Spain and involves 49 patients. Patients took 6 different ALK inhibitors. The abstract concluded “ALK+ patients who received targeted agents have prolonged survival despite brain metastases…. ALK inhibitors improve intracranial response rate and survival.”

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Discontinuing Crizotinib treatment

Abstract e20610 is from Canada and covers 97 patients. Post Crizotinib treatment 43% received Ceritinib, 20% received chemo and 37% received no additional treatment. Median overall survival was: 0.9 months for those who received no additional treatment, 7.6 months for … Continue reading

Posted in ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Long term phase 1 data for Ceritinib

On March 10 an article was published on the long term results of a phase 1 trial of Ceritinib. The trial enrolled 255 patients from January 2011 and July 2013 of whom 246 had ALK + lung cancer. Data cutoff … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment, Side Effects | Leave a comment

Article by Dr. Shaw

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA. http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, Lung cancer, Potential Treatments, Research | Leave a comment

Editorial on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients that discusses ALK inhibitors and different kinds of radiation treatments. Treatments discussed include: 1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Survey of ALK inhibitors effects on brain mets

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment